Author - Channel Manager

Syd Labs体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体

Syd Labs 体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体

Syd Labs 体内实验级重组抗小鼠PD-(L)1 / VEGF双特异性抗体(抗小鼠PD-1/VEGF双抗、抗小鼠PD-L1/VEGF双抗)是用哺乳动物细胞生产的重组抗体，多用于动物肿瘤模型研究，可与对应分型的双特异性同型对照抗体配套使用。如要订购，欢迎咨询！

2026年8月4日技术文章, , , , , , , , Read more...
Figure 1 The effect of anti-PD-1 and anti-CTLA-4 antibodies on the tumor growth in B16-F10-bearing mice. (A) A schematic diagram illustrating the chronological events of experiments (n=8). (B) Tumor growth kinetics in anti-PD-1 day 1-4-7, anti-PD-1 day 11-14-17 or anti-CTLA-4 day 1-4-7 treated B16-F10-bearing mice, compared with vehicle (n=2). Data are mean ± SEM. (C,D,E,F,G,H) The correlation of tumor size and tumor-infiltrating and splenic immune cell population infiltrating CD45+CD3+ (C), CD45+CD3+CD8+ T cells (D), CD45+CD3+CD4+ T cells (E) and CD45+CD11b+ myeloid cells (F), splenic CD45+CD3+CD8+ (G) and CD45+CD3+CD4+ T cells (H). VE, vehicle; PD1, anti-PD-1 day 1-4-7; PD11, anti-PD-1 day 11-14-17; CT, anti-CTLA-4 day 1-4-7; PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.

抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中剂量建议

抗小鼠CTLA-4单抗（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在B16黑色素瘤模型中的注射剂量如何确定？欢迎参考本文。

2026年8月3日技术文章, , , , , , , Read more...

抗小鼠CTLA-4抗体(9D9)在MC38结肠腺癌模型中剂量建议

抗小鼠CTLA-4抗体（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在MC38结肠腺癌模型中的注射剂量怎么确定？欢迎参考本文。

2026年8月3日技术文章, , , , , , , Read more...
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.

抗小鼠CTLA-4抗体(9D9)在EMT6乳腺癌模型中剂量建议

抗小鼠CTLA-4抗体（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在EMT6乳腺癌模型中的注射剂量怎么确定？欢迎参考本文。

2026年8月3日技术文章, , , , , , , Read more...

重组抗体年中大促！买同型对照抗体送40%重组抗体优惠券

Syd Labs 买同型对照抗体送40%重组抗体优惠券：活动期间内购买同型对照抗体， 即可获得40%重组抗体优惠券。活动时间：2026年5月18日-6月30日。产品仅限于科研使用，不得用于人类或动物的诊断或治疗。如要订购，欢迎咨询！

2026年8月3日产品新闻, , , , , , , , , , , , , , Read more...

深圳麦科龙生物科技有限公司

深圳麦科龙生物科技有限公司代理品牌包括四正柏、乔默生物、BioLegend等。页面内容根据公开资料整理，仅供参考；如果您需要了解深圳麦科龙生物科技有限公司的更多信息，例如法定代表人（联系电话：137XXX）等，欢迎联系我们！

2026年8月3日渠道商信息Read more...
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.
Figure 1 The effect of anti-PD-1 and anti-CTLA-4 antibodies on the tumor growth in B16-F10-bearing mice. (A) A schematic diagram illustrating the chronological events of experiments (n=8). (B) Tumor growth kinetics in anti-PD-1 day 1-4-7, anti-PD-1 day 11-14-17 or anti-CTLA-4 day 1-4-7 treated B16-F10-bearing mice, compared with vehicle (n=2). Data are mean ± SEM. (C,D,E,F,G,H) The correlation of tumor size and tumor-infiltrating and splenic immune cell population infiltrating CD45+CD3+ (C), CD45+CD3+CD8+ T cells (D), CD45+CD3+CD4+ T cells (E) and CD45+CD11b+ myeloid cells (F), splenic CD45+CD3+CD8+ (G) and CD45+CD3+CD4+ T cells (H). VE, vehicle; PD1, anti-PD-1 day 1-4-7; PD11, anti-PD-1 day 11-14-17; CT, anti-CTLA-4 day 1-4-7; PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.
Figure 4 CTLA-4 blockade is less effective in aged mice. CT26 tumor cells were subcutaneously implanted on the flank of female BALB/c mice either at 6-8 weeks old (young) or at 60-72 weeks old (aged). (A, B) The mice were treated with anti-CTLA-4 antibody IP at 10 mg/kg twice weekly starting 7 days after tumor cell implantation for a total of 6 doses. (A) Kaplan-Meier curves showing time-to-welfare endpoint. 38 mice per group. (B) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-CTLA-4 antibody treatment compared to age-matched untreated mice. 38 mice per group. (C, D) The mice were treated IP at 10 mg/kg twice weekly for a total of 6 doses with a combination of anti-PD-L1 antibody (starting 4 days after tumor cell implantation) and anti-CTLA-4 antibody (starting 7 days after tumor cell implantation). (C) Kaplan-Meier curves showing time-to-welfare endpoint. 37-38 mice per group. (D) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-PD-L1 and anti-CTLA-4 antibodies compared to age-matched untreated mice. 37-38 mice per group. The results in panels (A, B) include data from 3 experiments and the results in panels (C, D) include data from 4 experiments. ns, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.

9D9抗体在不同小鼠肿瘤模型中剂量建议

9D9抗体（抗小鼠CTLA-4单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在不同小鼠肿瘤模型中的注射剂量如何确定？欢迎参考本文。

2026年8月2日技术文章, , , , , , , , , , , , , , , , , Read more...